Alnylam Pharmaceuticals (ALNY) Enterprise Value (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Enterprise Value came in at -$3.3 billion in Q2 2026, down 15.77% YoY from -$3.9 billion in Q2 2025, and down 9.93% on a QoQ basis from -$3.0 billion in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Enterprise Value (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Enterprise Value data on file, last reported at -$3.3 billion in Q2 2026.
- Quarterly Enterprise Value fell 15.77% year-over-year to -$3.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$3.3 billion (down 15.77% YoY) and the FY2025 annual result came in at -$2.9 billion, down 8.18% from the prior year.
- Enterprise Value fell to -$3.3 billion in Q2 2026, from -$3.0 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.0 billion in Q2 2023 to a low of -$3.3 billion in Q2 2026.
- A 5-year average of -$2.5 billion and a median of -$2.5 billion in 2023 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 8.62% in 2022, down 33.58% in 2022.
- Tracing ALNY's Enterprise Value over 5 years: stood at -$2.2 billion in 2022, then decreased by 12.08% to -$2.4 billion in 2023, then dropped by 10.72% to -$2.7 billion in 2024, then dropped by 8.18% to -$2.9 billion in 2025, then retreated by 13.74% to -$3.3 billion in 2026.
- The last three Enterprise Value figures came in at -$3.3 billion (Q2 2026), -$3.0 billion (Q1 2026), and -$2.9 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -3.15 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.31 Bn |
| Mar 31, 2026 | -3.01 Bn |
| Dec 31, 2025 | -2.91 Bn |
| Sep 30, 2025 | -1.49 Bn |
| Jun 30, 2025 | -1.11 Bn |
| Mar 31, 2025 | -2.63 Bn |
| Dec 31, 2024 | -976.81 Mn |
| Sep 30, 2024 | -1.11 Bn |
| Jun 30, 2024 | -2.61 Bn |
| Mar 31, 2024 | -693.14 Mn |
| Dec 31, 2023 | -2.43 Bn |
| Sep 30, 2023 | -1.04 Bn |
| Jun 30, 2023 | -685.06 Mn |
| Mar 31, 2023 | -698.10 Mn |
| Dec 31, 2022 | -2.17 Bn |
| Sep 30, 2022 | -1.10 Bn |
| Jun 30, 2022 | -606.46 Mn |
| Mar 31, 2022 | -2.21 Bn |
| Dec 31, 2021 | -889.13 Mn |
| Sep 30, 2021 | -1.17 Bn |